Vor Biopharma (VOR) Competitors $2.10 +0.03 (+1.45%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.04 -0.06 (-2.86%) As of 08/1/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VOR vs. GHRS, AKBA, SANA, AMPH, ZYME, COLL, SYRE, RCUS, VERV, and AVXLShould you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include GH Research (GHRS), Akebia Therapeutics (AKBA), Sana Biotechnology (SANA), Amphastar Pharmaceuticals (AMPH), Zymeworks (ZYME), Collegium Pharmaceutical (COLL), Spyre Therapeutics (SYRE), Arcus Biosciences (RCUS), Verve Therapeutics (VERV), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. Vor Biopharma vs. Its Competitors GH Research Akebia Therapeutics Sana Biotechnology Amphastar Pharmaceuticals Zymeworks Collegium Pharmaceutical Spyre Therapeutics Arcus Biosciences Verve Therapeutics Anavex Life Sciences GH Research (NASDAQ:GHRS) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment. Do institutionals and insiders hold more shares of GHRS or VOR? 56.9% of GH Research shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 2.9% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is GHRS or VOR more profitable? Vor Biopharma's return on equity of 0.00% beat GH Research's return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -19.20% -18.40% Vor Biopharma N/A N/A N/A Do analysts prefer GHRS or VOR? GH Research currently has a consensus price target of $32.00, suggesting a potential upside of 132.90%. Vor Biopharma has a consensus price target of $5.63, suggesting a potential upside of 168.03%. Given Vor Biopharma's higher probable upside, analysts clearly believe Vor Biopharma is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Vor Biopharma 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more volatility and risk, GHRS or VOR? GH Research has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Which has preferable valuation & earnings, GHRS or VOR? GH Research is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$38.96M-$0.79-17.39Vor BiopharmaN/AN/AN/A-$1.51-1.39 Does the media prefer GHRS or VOR? In the previous week, Vor Biopharma had 2 more articles in the media than GH Research. MarketBeat recorded 4 mentions for Vor Biopharma and 2 mentions for GH Research. Vor Biopharma's average media sentiment score of 0.83 beat GH Research's score of 0.34 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vor Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryVor Biopharma beats GH Research on 8 of the 12 factors compared between the two stocks. Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VOR vs. The Competition Export to ExcelMetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryMedical SectorNYSE ExchangeMarket Cap$262.42M$229.22M$5.48B$20.69BDividend YieldN/AN/A4.73%3.67%P/E Ratio-1.27N/A28.6729.07Price / SalesN/AN/A373.5466.37Price / CashN/AN/A35.4522.84Price / BookN/AN/A8.274.43Net IncomeN/AN/A$3.24B$994.22M7 Day Performance-4.55%-13.67%-3.69%-3.35%1 Month Performance44.83%18.99%4.33%-2.06%1 Year Performance142.77%142.77%25.95%10.15% Vor Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VORVor Biopharma3.2875 of 5 stars$2.10+1.4%$5.63+168.0%+123.4%$262.42MN/A-1.27140Gap DownGHRSGH Research2.2656 of 5 stars$19.50+11.0%$32.00+64.1%+11.4%$1.01BN/A-24.6810AKBAAkebia Therapeutics3.7291 of 5 stars$3.84-0.5%$6.75+75.8%+188.4%$1.01B$160.18M-18.28430News CoveragePositive NewsUpcoming EarningsSANASana Biotechnology3.1785 of 5 stars$4.44-4.1%$9.17+106.5%-27.1%$1.00BN/A-5.05380News CoverageUpcoming EarningsGap DownAMPHAmphastar Pharmaceuticals4.3834 of 5 stars$21.19+2.8%$32.33+52.6%-50.0%$998.90M$731.97M7.682,028News CoverageUpcoming EarningsZYMEZymeworks2.872 of 5 stars$14.32+0.5%$21.00+46.6%+24.3%$997.86M$93.38M-9.55460Upcoming EarningsCOLLCollegium Pharmaceutical4.0387 of 5 stars$30.91-0.9%$43.75+41.5%-22.1%$993.14M$631.45M25.34210Upcoming EarningsSYRESpyre Therapeutics2.3063 of 5 stars$16.35+0.4%$53.40+226.6%-39.6%$985.58M$890K-4.3473News CoveragePositive NewsUpcoming EarningsGap DownRCUSArcus Biosciences2.1528 of 5 stars$9.27+1.3%$21.29+129.7%-41.8%$981.18M$258M-2.21500Upcoming EarningsVERVVerve Therapeutics3.3594 of 5 stars$10.93+0.2%$14.57+33.3%N/A$974.30M$32.33M-5.18110News CoverageAVXLAnavex Life Sciences3.6596 of 5 stars$11.16+1.6%$44.00+294.3%+70.2%$953.29MN/A-20.2940News CoverageUpcoming Earnings Related Companies and Tools Related Companies GHRS Competitors AKBA Competitors SANA Competitors AMPH Competitors ZYME Competitors COLL Competitors SYRE Competitors RCUS Competitors VERV Competitors AVXL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:VOR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
